NCT00707902 is a Phase 3 clinical trial of chlorhexidine/lidocaine in Pharyngitis, sponsored by A. Vogel AG.

Who is sponsoring NCT00707902?

NCT00707902 is sponsored by A. Vogel AG.

What drugs are being tested in NCT00707902?

Interventions in NCT00707902: chlorhexidine/lidocaine, echinacea/sage.

What condition does NCT00707902 study?

NCT00707902 studies Pharyngitis.

Is NCT00707902 still recruiting?

NCT00707902 is currently completed. Last updated 30 June 2008.

Last reviewed 2008-06-30 · How we verify

NCT00707902

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Multicentric Randomized Double Blind Double Dummy Placebo Controlled Clinical Trial for Assessment of Safety and Efficacy of a Echinacea/Sage Spray in Comparison to a Chlorhexidine/Lidocaine Spray in the Treatment of Acute Sore Throats

Completed Phase 3 Last updated 30 June 2008

What this trial tests

Phase 3 trial testing chlorhexidine/lidocaine in Pharyngitis in 154 participants. Completed in 1 August 2006.

Timeline

1 February 2006

1 August 2006

Quick facts

Lead sponsor	A. Vogel AG
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	154
Start date	1 February 2006
Estimated completion	1 August 2006
Sites	1 location across Switzerland

Drugs / interventions tested

chlorhexidine/lidocaine — full drug profile →
echinacea/sage — full drug profile →

Conditions studied

Pharyngitis — all drugs for Pharyngitis →

Sponsor

A. Vogel AG — full company profile →

Who can join

Adults 12 to 75, any sex, with Pharyngitis. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

comparison of responder of the two treatment groups after the first, second, and third days. A responder is defined as a reduction by 50% of the total baseline score taken prior to treatment start.
Time frame: first three days of treatment

Sponsor's own description

The aim of the study is to show non-inferiority of an echinacea/sage spray compared to a chlorhexidine/lidocaine-spray in the treatment of acute sore throat during five days of treatment. Main outcome parameter is the non-inferiority in number of responders between the two treatment groups. A responder is defined as a reduction by 50% of the total baseline score taken prior to treatment start. The symptoms are assessed with a symptom score.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Echinacea/sage or chlorhexidine/lidocaine for treating acute sore throats: a randomized double-blind trial.
Schapowal A, Berger D, Klein P, Suter A. · · 2009 · cited 17× · PMID 19748859 · DOI 10.1186/2047-783x-14-9-406

Verify or expand the search:

Other recruiting trials for Pharyngitis

Currently open trials in the same condition.

NCT06859281 — Safety, Tolerability, and Pharmacokinetic Profile of Grammidin, a Metered Dose Topical Spray in Healthy Volunteers · Phase 1 · recruiting
NCT06857890 — Safety, Tolerability, and Pharmacokinetic Profile of Grammidin With Anesthetic, a Metered Dose Topical Spray in Healthy · Phase 1 · recruiting
NCT06843018 — Study to Evaluate the Efficacy and Safety of Different Doses of Graminidin With Anesthetic, a Metered Dose Topical Spray · Phase 2 · recruiting
NCT06114706 — Best Assessment of Sore Throat and Antibiotic Prescribing · NA · recruiting
NCT04471493 — Pediatric and Ambulatory Research in Infectious Diseases · recruiting

Other A. Vogel AG trials

Trials by the same sponsor.

NCT06795776 — Eschscholzia Study · Phase 3 · completed
NCT05748574 — Sleep Well Observation Study · NA · completed
NCT05757050 — Mental Balance Study · NA · completed
NCT04999098 — Echinaforce COVID-19 Shedding Study · Phase 4 · terminated
NCT05002179 — Echinaforce Study to Investigate Explorative Pharmacology and Effectiveness to Prevent From Enveloped Virus Infections · Phase 4 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00707902 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by A. Vogel AG
Last refreshed: 30 June 2008

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00707902.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing